• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Axcella Health Inc. filed SEC Form 8-K: Regulation FD Disclosure

    12/22/23 4:30:17 PM ET
    $AXLA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AXLA alert in real time by email
    false 0001633070 0001633070 2023-12-21 2023-12-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d)
    of The Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): December 21, 2023

     

    AXCELLA HEALTH INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-38901   26-3321056
    (State or other jurisdiction
    of incorporation)
      (Commission
    File Number)
      (IRS Employer
    Identification No.)

     

    124 Washington Street, Suite 101
    Foxboro
    , Massachusetts
    02035
    (Address of principal executive offices) (Zip Code)

     

    Registrant's telephone number, including area code: (857) 320-2200

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which
    registered
    Common Stock, $0.001 Par Value   AXLA   OTC Markets

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

      

     

     

     

    Item 7.01. Regulation FD Disclosure.

     

    In furtherance of its liquidation and dissolution (the “Dissolution”) pursuant to its Plan of Liquidation and Dissolution (the “Plan of Dissolution”), Axcella Health Inc. (“Axcella”) intends to file a certificate of dissolution with the Secretary of State of the State of Delaware immediately following the close of regular trading on the OTC Markets (“OTC”) on December 28, 2023.

     

    Upon the filing of the certificate of dissolution, Axcella will close its stock transfer books, after which record holders of Axcella’s common stock, par value $0.001 per share (the “Shares”) will be prohibited from transferring record ownership of their Shares, except by will, intestate succession or operation of law.

     

    As previously announced, Axcella’s stockholders approved the Dissolution pursuant to the Plan of Dissolution at a special meeting of stockholders held on December 4, 2023. Additional information regarding the Plan of Dissolution and the Dissolution process can be found in Axcella’s Definitive Proxy Statement on Schedule 14A filed with the SEC on November 17, 2023.

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Axcella Health Inc.
       
    Date: December 22, 2023 By: /s/ Craig R. Jalbert
      Name:   /s/ Craig R. Jalbert
      Title: President, Chief Executive Officer and Sole Director

     

     

     

    Get the next $AXLA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AXLA

    DatePrice TargetRatingAnalyst
    11/16/2021$10.00 → $12.00Buy
    Chardan Capital
    10/12/2021$6.00Outperform
    Noble Capital Markets
    9/22/2021$9.00 → $5.00Buy → Neutral
    Goldman Sachs
    7/30/2021Neutral → Underweight
    JP Morgan
    7/6/2021$14.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $AXLA
    SEC Filings

    See more
    • SEC Form 25-NSE filed by Axcella Health Inc.

      25-NSE - Axcella Health Inc. (0001633070) (Subject)

      2/15/24 8:54:23 AM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Axcella Health Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Axcella Health Inc. (0001633070) (Filer)

      12/22/23 4:30:17 PM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Axcella Health Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets

      8-K - Axcella Health Inc. (0001633070) (Filer)

      12/19/23 4:45:12 PM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AXLA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Axcella Announces Reverse Stock Split Effective September 19, 2023

      – AXLA common stock expected to begin trading on a split-adjusted basis on September 19, 2023 – Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions of endogenous metabolic modulators (EMMs), today announced that its Board of Directors has approved a 1-for-25 reverse stock split of the Company's common stock. The reverse stock split will become effective at 5:00 p.m. Eastern Time on September 18, 2023, after close of trading on The Nasdaq Global Market. The Company's common stock is expected to commence trading on a split-adjusted basis when the markets open on Septembe

      9/14/23 4:30:00 PM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Axcella Granted Patent for Long COVID Fatigue Treatment

      Claims cover methods of treating a subject presenting with fatigue from post-acute sequelae of COVID-19 (PASC), a/k/a Long COVID, with Candidate AXA1125 Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions of endogenous metabolic modulators (EMMs), today announced that the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent No. 11,737,999 with claims covering methods of use of Candidate AXA1125, for treating a subject having post-acute sequelae of COVID-19 (PASC), a/k/a Long COVID, particularly fatigue. The patent was issued on August 29, 2023, with anticip

      8/29/23 8:00:00 AM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Axcella Reports Second Quarter Financial Results and Provides Business Update

      AXA1125 remains the most advanced product to help patients experiencing fatigue post acute COVID-19 The Company continues to pursue a strategic alternative for stakeholders Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions of endogenous metabolic modulators (EMMs), today announced financial results for the second quarter ended June 30, 2023 and provided a business update. "Patients are seeking relief from Long COVID fatigue. Axcella's proprietary composition of amino acids in AXA1125 in Long COVID fatigue is potentially an important step to help people mainta

      8/3/23 7:30:00 AM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AXLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Koziel Margaret

      4 - Axcella Health Inc. (0001633070) (Issuer)

      2/24/23 4:18:54 PM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Fehlner Paul

      4 - Axcella Health Inc. (0001633070) (Issuer)

      2/24/23 4:17:30 PM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Hinshaw William

      4 - Axcella Health Inc. (0001633070) (Issuer)

      2/24/23 4:18:21 PM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AXLA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital reiterated coverage on Axcella Health with a new price target

      Chardan Capital reiterated coverage of Axcella Health with a rating of Buy and set a new price target of $12.00 from $10.00 previously

      11/16/21 9:26:58 AM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Noble Capital Markets initiated coverage on Axcella Health with a new price target

      Noble Capital Markets initiated coverage of Axcella Health with a rating of Outperform and set a new price target of $6.00

      10/12/21 8:46:44 AM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Axcella Health downgraded by Goldman Sachs with a new price target

      Goldman Sachs downgraded Axcella Health from Buy to Neutral and set a new price target of $5.00 from $9.00 previously

      9/22/21 6:18:00 AM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care